BLSM
BlossomHill Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.01
+9.94%Income statement
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | ||
| Total Revenue | — | — |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Operating Expenses | ||
| R&D Expense | 56.1M | 31.8M |
| SG&A Expense | 7.9M | 4.6M |
| General & Admin Expense | 7.9M | 4.6M |
| Selling & Marketing Expense | — | — |
| Other Expenses | — | — |
| Total Operating Expenses | 64.0M | 36.4M |
| Cost and Expenses | 64.0M | 36.4M |
| Operating Income (EBIT) | (64.0M) | (36.4M) |
| Non-Operating | ||
| Interest Income | 3.5M | 5.7M |
| Interest Expense | — | — |
| Net Interest Income | 3.5M | 5.7M |
| Other Non-Op Income/Expense | 3.5M | 5.7M |
| Non-Operating Income (excl Interest) | — | — |
| EBT (Pre-Tax Income) | (60.6M) | (30.7M) |
| Income Tax Expense | — | — |
| Bottom Line | ||
| Net Income | (60.6M) | (30.7M) |
| Earnings from Cont. Ops | (60.6M) | (30.7M) |
| Earnings from Discont. Ops | — | — |
| Bottom Line Net Income | (60.6M) | (30.7M) |
| Per Share | ||
| Basic EPS | ($2.08) | ($1.06) |
| Diluted EPS | ($2.08) | ($1.06) |
| Revenue Per Share | $0.00 | $0.00 |
| Shares | ||
| Basic Shares Outstanding | 29.1M | 29.1M |
| Diluted Shares Outstanding | 29.1M | 29.1M |
| Profitability Metrics | ||
| EBITDA | (63.6M) | (36.1M) |
| D&A | 441.0K | 350.0K |
| EBIT | (64.0M) | (36.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026